News
| 2 min read
PRX-102 concludes Phase 3 trial in Fabry disease, improves renal function
| 3 min read
The companies will advance the gonadotropin-releasing hormone receptor antagonist in advanced prostate cancer and two women's health indications
| 3 min read
Altimmune begins Phase 2 clinical trial of HepTcell, an immunotherapeutic for chronic hepatitis B
| 2 min read
Dapansutrile prevents inflammatory response, and restores cognitive and behavioral deficits in an Alzheimer’s mouse model
| 2 min read
Soligenix gains a $1.5 million Small Business Innovation Research award for COVID-19 and ebola vaccines
| 3 min read
Researchers find that chromothripsis results in rearranged genomes and ecDNA that helps mutated cells evade treatment
| 3 min read
The companies will collaborate on an allogeneic cell therapy candidate for solid tumor cancers
| 2 min read
The deal nets Servier a clinical oncology portfolio and will expand its U.S. footprint
| 2 min read
Resverlogix publishes work in PNAS detailing how BET inhibition was found to reduce SARS-CoV-2 infection in mice and human cell lines
| 2 min read
AMG 634, an investigational treatment for tuberculosis and leprosy, has been licensed to Medicines Development for Global Health
| 3 min read
NBE-Therapeutics will remain at its Basel, Switzerland, campus and operate within Boehringer Ingelheim’s R&D network
| 2 min read
Positive initial casirivimab and imdevimab results in non-hospitalized COVID-19 patients were published in NEJM
